WO2001037876A3 - Methods of ameliorating abnormal bone states - Google Patents

Methods of ameliorating abnormal bone states Download PDF

Info

Publication number
WO2001037876A3
WO2001037876A3 PCT/EP2000/011466 EP0011466W WO0137876A3 WO 2001037876 A3 WO2001037876 A3 WO 2001037876A3 EP 0011466 W EP0011466 W EP 0011466W WO 0137876 A3 WO0137876 A3 WO 0137876A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
hmg
abnormal bone
prevention
treatment
Prior art date
Application number
PCT/EP2000/011466
Other languages
French (fr)
Other versions
WO2001037876A2 (en
Inventor
Cedo M Bagi
Original Assignee
Bayer Ag
Cedo M Bagi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Cedo M Bagi filed Critical Bayer Ag
Priority to AU20007/01A priority Critical patent/AU2000701A/en
Publication of WO2001037876A2 publication Critical patent/WO2001037876A2/en
Publication of WO2001037876A3 publication Critical patent/WO2001037876A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This application relates to methods of using 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors for the prevention and for the treatment of abnormal conditions ameliorated by concurrent decrease in bone resorption and stimulation of bone formation, comprising administering a therapeutically effective amount of a HMG-Co A reductase inhibitor to a vertebrate in need thereof. This invention also relates to methods of using HMG-CoA reductase inhibitors for the prevention and for the treatment of conditions ameliorated by a decrease in plasma calcium levels.
PCT/EP2000/011466 1999-11-24 2000-11-17 Methods of ameliorating abnormal bone states WO2001037876A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU20007/01A AU2000701A (en) 1999-11-24 2000-11-17 Methods of ameliorating abnormal bone states

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16726799P 1999-11-24 1999-11-24
US60/167,267 1999-11-24

Publications (2)

Publication Number Publication Date
WO2001037876A2 WO2001037876A2 (en) 2001-05-31
WO2001037876A3 true WO2001037876A3 (en) 2002-03-21

Family

ID=22606650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/011466 WO2001037876A2 (en) 1999-11-24 2000-11-17 Methods of ameliorating abnormal bone states

Country Status (2)

Country Link
AU (1) AU2000701A (en)
WO (1) WO2001037876A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376476B1 (en) * 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
JP2002370982A (en) * 2001-06-12 2002-12-24 Kowa Co Osteogenesis promoter
EP1291017A3 (en) * 2001-09-10 2003-07-02 Warner-Lambert Company Use of statins to inhibit formation of osteoclasts
SI21400A (en) * 2003-02-12 2004-08-31 LEK farmacevtska družba d.d. Stable pharmaceutical form with hmg-coa reductase inhibitor
SI21402A (en) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Lined particles and pharmaceutical forms
US7199126B2 (en) 2004-04-29 2007-04-03 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7183285B2 (en) 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7163945B2 (en) 2004-04-29 2007-01-16 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
AU2005263550C1 (en) 2004-07-16 2013-01-17 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
TWI382841B (en) * 2010-10-29 2013-01-21 Univ China Medical Pharmaceutical composition for inhibiting inflammation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025460A1 (en) * 1996-12-13 1998-06-18 Zymogenetics, Inc. Compositions and methods for stimulating bone growth
WO1999045923A1 (en) * 1998-03-13 1999-09-16 Merck & Co., Inc. Methods of inhibiting bone resorption

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025460A1 (en) * 1996-12-13 1998-06-18 Zymogenetics, Inc. Compositions and methods for stimulating bone growth
WO1999045923A1 (en) * 1998-03-13 1999-09-16 Merck & Co., Inc. Methods of inhibiting bone resorption

Also Published As

Publication number Publication date
WO2001037876A2 (en) 2001-05-31
AU2000701A (en) 2001-06-04

Similar Documents

Publication Publication Date Title
PT1509232E (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer`s disease
WO2003057165A3 (en) COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS
MXPA04005790A (en) Compounds and uses thereof for decreasing activity of hormone-sensitive lipase.
WO2003032914A3 (en) Methods for treating substance abuse with cholinesterase inhibitors
WO2001068096A3 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
AU2003225295A1 (en) Substituted pyrroline kinase inhibitors
IN2005KO00312A (en)
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MXPA03006248A (en) Fumaric acid derivatives as nf-kappab inhibitors.
EP1578414A4 (en) Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004108157A8 (en) Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
WO2001081310A8 (en) 1-aroyl-piperidinyl benzamidines
MY140080A (en) Treatment and prevention of osteoporosis
PT1365762E (en) Method for increasing leptin levels using nicotinic acid compounds
TNSN08153A1 (en) Anti-hypercholesterolemic compounds
WO2002009814A3 (en) New use of lipase inhibitors
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
WO2001037876A3 (en) Methods of ameliorating abnormal bone states
TNSN05306A1 (en) Substituted pyrrole derivatives.
MXPA06000705A (en) Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders.
WO2003094909A3 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
AP2001002248A0 (en) Method for treating COPD.
MY131170A (en) Therapeutic agent for glomerular disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase